Close Menu

North America

Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.

The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.

Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.

The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.

Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.

The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.

Pages